Crescendo Biologics Ltd (Crescendo) today announces that it has signed collaborations with world-renowned oncology research groups at the University of Oxford and the University of Surrey. These collaborations will accelerate the development of CB307, Crescendo’s lead programme for PSMA positive tumours, and its follow-on pipeline of CD137-directed T cell enhancing programmes.
Crescendo Biologics to collaborate with world-leading oncology groups at the University of Oxford and the University of Surrey
Immatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies
Immatics Biotechnologies GmbH, today announced that Immatics and Celgene Corporation have entered into a strategic collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers.
Immatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients
Immatics Biotechnologies GmbH, announced today a comprehensive data set having completed the first cohort of the ACTolog® Personalized Multi-Target T-cell Therapy Trial (Study code: IMA101-101, NCT02876510) at the AACR Special Conference on Immune Cell Therapies for Cancer.